Is there a clinical role for oxidative stress biomarkers in atherosclerotic diseases?

Internal and Emergency Medicine

Volumn 9, Issue 2, 2014, Pages 123-131

  Pastori, Daniele ^a   Carnevale, Roberto ^a   Pignatelli, Pasquale ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Atherosclerosis; Biomarkers; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN; PEROXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ATHEROSCLEROSIS; HUMAN; METABOLISM; OXIDATIVE STRESS; RISK ASSESSMENT;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; ISOPROSTANES; LIPOPROTEINS, LDL; NADPH OXIDASE; OXIDATIVE STRESS; PEROXIDASE; RISK ASSESSMENT;

EID: 84894504338     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-013-0999-6     Document Type: Review

References (80)

1. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F (2012) European Association for Cardiovascular P, Rehabilitation, Guidelines ESCCfP (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version, The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33(13): 1635-1701. doi: 10. 1093/eurheartj/ehs092.
2. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340(2): 115-126.
3. Stocker R, Keaney JF Jr (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84(4): 1381-1478.
4. Morrow JD (2005) Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 25(2): 279-286. doi: 10. 1161/01. ATV. 0000152605. 64964. c0.
5. Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44(2): 129-146. doi: 10. 1007/s001250051591.
6. Li H, Horke S, Förstermann U (2013) Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol Sci 34(6): 313-319. doi: 10. 1016/j. tips. 2013. 03. 007.
7. Schaub N, Reichlin T, Meune C, Twerenbold R, Haaf P, Hochholzer W, Niederhauser N, Bosshard P, Stelzig C, Freese M, Reiter M, Gea J, Buser A, Mebazaa A, Osswald S, Mueller C (2012) Markers of plaque instability in the early diagnosis and risk stratification of acute myocardial infarction. Clin Chem 58(1): 246-256.
8. Violi F, Basili S, Nigro C, Pignatelli P (2009) Role of NADPH oxidase in atherosclerosis. Future Cardiol 5(1): 83-92.
9. Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87(10): 840-844.
10. Campia U, Tesauro M, Cardillo C (2012) Human obesity and endothelium-dependent responsiveness. Br J Pharmacol 165(3): 561-573. doi: 10. 1111/j. 1476-5381. 2011. 01661. x.
11. Babior BM, Lambeth JD, Nauseef W (2002) The neutrophil NADPH oxidase. Arch Biochem Biophys 397(2): 342-344. doi: 10. 1006/abbi. 2001. 2642.
12. Loffredo L (2011) Chronic granulomatous disease. Intern Emerg Med 6(Suppl 1): 125-128. doi: 10. 1007/s11739-011-0676-6.
13. Pignatelli P, Carnevale R, Cangemi R, Loffredo L, Sanguigni V, Stefanutti C, Basili S, Violi F (2010) Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 30(2): 360-367. doi: 10. 1161/ATVBAHA. 109. 198622.
14. Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87(1): 245-313. doi: 10. 1152/physrev. 00044. 2005.
15. Khatri JJ, Johnson C, Magid R, Lessner SM, Laude KM, Dikalov SI, Harrison DG, Sung HJ, Rong Y, Galis ZS (2004) Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 109(4): 520-525. doi: 10. 1161/01. CIR. 0000109698. 70638. 2B.
16. Loffredo L, Martino F, Carnevale R, Pignatelli P, Catasca E, Perri L, Calabrese CM, Palumbo MM, Baratta F, Del Ben M, Angelico F, Violi F (2012) Obesity and hypercholesterolemia are associated with NOX2 generated oxidative stress and arterial dysfunction. J Pediatr 161(6): 1004-1009. doi: 10. 1016/j. jpeds. 2012. 05. 042.
17. Del Ben M, Fabiani M, Loffredo L, Polimeni L, Carnevale R, Baratta F, Brunori M, Albanese F, Augelletti T, Violi F, Angelico F (2012) Oxidative stress mediated arterial dysfunction in patients with obstructive sleep apnoea and the effect of continuous positive airway pressure treatment. BMC Pulm Med 12: 36. doi: 10. 1186/1471-2466-12-36.
18. Carnevale R, Loffredo L, Pignatelli P, Nocella C, Bartimoccia S, Di Santo S, Martino F, Catasca E, Perri L, Violi F (2012) Dark chocolate inhibits platelet isoprostanes via NOX2 down-regulation in smokers. J Thromb Haemost: JTH 10(1): 125-132. doi: 10. 1111/j. 1538-7836. 2011. 04558. x.
19. Loffredo L, Carnevale R, Cangemi R, Angelico F, Augelletti T, Di Santo S, Calabrese CM, Della Volpe L, Pignatelli P, Perri L, Basili S, Violi F (2012) NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. Int J Cardiol. doi: 10. 1016/j. ijcard. 2012. 01. 069.
20. Violi F, Sanguigni V, Loffredo L, Carnevale R, Buchetti B, Finocchi A, Tesauro M, Rossi P, Pignatelli P (2006) Nox2 is determinant for ischemia-induced oxidative stress and arterial vasodilatation: a pilot study in patients with hereditary Nox2 deficiency. Arterioscler Thromb Vasc Biol 26(8): e131-e132. doi: 10. 1161/01. ATV. 0000229710. 13054. 2d.
21. Loffredo L, Carnevale R, Sanguigni V, Plebani A, Rossi P, Pignata C, De Mattia D, Finocchi A, Martire B, Pietrogrande MC, Martino S, Gambineri E, Giardino G, Soresina AR, Martino F, Pignatelli P, Violi F (2013) Does NADPH oxidase deficiency cause artery dilatation in humans? Antioxid redox signal 18(12): 1491-1496.
22. Angelico F, Loffredo L, Pignatelli P, Augelletti T, Carnevale R, Pacella A, Albanese F, Mancini I, Di Santo S, Del Ben M, Violi F (2012) Weight loss is associated with improved endothelial dysfunction via NOX2-generated oxidative stress down-regulation in patients with the metabolic syndrome. Intern Emerg Med 7(3): 219-227. doi: 10. 1007/s11739-011-0591-x.
23. Basili S, Pignatelli P, Tanzilli G, Mangieri E, Carnevale R, Nocella C, Di Santo S, Pastori D, Ferroni P, Violi F (2011) Anoxia-reoxygenation enhances platelet thromboxane A2 production via reactive oxygen species-generated NOX2: effect in patients undergoing elective percutaneous coronary intervention. Arterioscler Thromb Vasc Biol 31(8): 1766-1771. doi: 10. 1161/ATVBAHA. 111. 227959.
24. Violi F, Pignatelli P, Pignata C, Plebani A, Rossi P, Sanguigni V, Carnevale R, Soresina A, Finocchi A, Cirillo E, Catasca E, Angelico F, Loffredo L (2013) Reduced atherosclerotic burden in subjects with genetically determined low oxidative stress. Arterioscler Thromb Vasc Biol 33(2): 406-412. doi: 10. 1161/ATVBAHA. 112. 300438.
25. Liu Y, Davidson BP, Yue Q, Belcik T, Xie A, Inaba Y, McCarty OJ, Tormoen GW, Zhao Y, Ruggeri ZM, Kaufmann BA, Lindner JR (2013) Molecular imaging of inflammation and platelet adhesion in advanced atherosclerosis effects of antioxidant therapy with NADPH oxidase inhibition. Circ Cardiovasc Imaging 6(1): 74-82. doi: 10. 1161/CIRCIMAGING. 112. 975193.
26. Pignatelli P, Sanguigni V, Lenti L, Ferro D, Finocchi A, Rossi P, Violi F (2004) gp91phox-dependent expression of platelet CD40 ligand. Circulation 110(10): 1326-1329. doi: 10. 1161/01. CIR. 0000134963. 77201. 55.
27. Cangemi R, Celestini A, Calvieri C, Carnevale R, Pastori D, Nocella C, Vicario T, Pignatelli P, Violi F (2012) Different behaviour of NOX2 activation in patients with paroxysmal/persistent or permanent atrial fibrillation. Heart 98(14): 1063-1066. doi: 10. 1136/heartjnl-2012-301952.
28. Cangemi R, Celestini A, Del Ben M, Pignatelli P, Carnevale R, Proietti M, Calabrese CM, Basili S, Violi F (2012) Role of platelets in NOX2 activation mediated by TNFalpha in heart failure. Intern Emerg Med. doi: 10. 1007/s11739-012-0837-2.
29. Cangemi R, Pignatelli P, Carnevale R, Nigro C, Proietti M, Angelico F, Lauro D, Basili S, Violi F (2012) Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes 61(6): 1626-1632. doi: 10. 2337/db11-1243.
30. Pignatelli P, Carnevale R, Di Santo S, Bartimoccia S, Sanguigni V, Lenti L, Finocchi A, Mendolicchio L, Soresina AR, Plebani A, Violi F (2011) Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol 31(2): 423-434. doi: 10. 1161/ATVBAHA. 110. 217885.
31. Morrow JD, Roberts LJ II (1999) Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol 300: 3-12.
32. Violi F, Sanguigni V, Carnevale R, Plebani A, Rossi P, Finocchi A, Pignata C, De Mattia D, Martire B, Pietrogrande MC, Martino S, Gambineri E, Soresina AR, Pignatelli P, Martino F, Basili S, Loffredo L (2009) Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation 120(16): 1616-1622.
33. Hummel SL, Seymour EM, Brook RD, Kolias TJ, Sheth SS, Rosenblum HR, Wells JM, Weder AB (2012) Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension 60(5): 1200-1206. doi: 10. 1161/HYPERTENSIONAHA. 112. 202705.
34. Davi G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, Patrono C (2003) Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 107(25): 3199-3203. doi: 10. 1161/01. CIR. 0000074205. 17807. D0.
35. Davies SS, Roberts LJ II (2011) F2-isoprostanes as an indicator and risk factor for coronary heart disease. Free Radic Biol Med 50(5): 559-566. doi: 10. 1016/j. freeradbiomed. 2010. 11. 023.
36. Puccetti L, Santilli F, Pasqui AL, Lattanzio S, Liani R, Ciani F, Ferrante E, Ciabattoni G, Scarpini F, Ghezzi A, Auteri A, Davi G (2011) Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 214(1): 122-128. doi: 10. 1016/j. atherosclerosis. 2010. 10. 006.
37. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C (2002) Platelet activation in obese women: role of inflammation and oxidant stress. JAMA: J Am Med Assoc 288(16): 2008-2014.
38. Shishehbor MH, Zhang R, Medina H, Brennan ML, Brennan DM, Ellis SG, Topol EJ, Hazen SL (2006) Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med 41(11): 1678-1683. doi: 10. 1016/j. freeradbiomed. 2006. 09. 001.
39. Woodward M, Croft KD, Mori TA, Headlam H, Wang XS, Suarna C, Raftery MJ, MacMahon SW, Stocker R (2009) Association between both lipid and protein oxidation and the risk of fatal or non-fatal coronary heart disease in a human population. Clin Sci 116(1): 53-60. doi: 10. 1042/CS20070404.
40. Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T, Davi G, Cuccurullo F, Patrono C (2000) Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102(9): 1007-1013.
41. Ward NC, Croft KD, Blacker D, Hankey GJ, Barden A, Mori TA, Puddey IB, Beer CD (2011) Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls. Clin Sci 121(11): 501-507. doi: 10. 1042/CS20110215.
42. Iuliano L, Pratico D, Greco C, Mangieri E, Scibilia G, FitzGerald GA, Violi F (2001) Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol 37(1): 76-80.
43. LeLeiko RM, Vaccari CS, Sola S, Merchant N, Nagamia SH, Thoenes M, Khan BV (2009) Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. Am J Cardiol 104(5): 638-643. doi: 10. 1016/j. amjcard. 2009. 04. 047.
44. Carr AC, McCall MR, Frei B (2000) Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 20(7): 1716-1723.
45. Hazen SL, Heinecke JW (1997) 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Investig 99(9): 2075-2081. doi: 10. 1172/JCI119379.
46. Marsche G, Furtmuller PG, Obinger C, Sattler W, Malle E (2008) Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro. Cardiovasc Res 79(1): 187-194. doi: 10. 1093/cvr/cvn051.
47. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF Jr, Hazen SL (2004) Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110(9): 1134-1139. doi: 10. 1161/01. CIR. 0000140262. 20831. 8F.
48. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P (2001) Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 158(3): 879-891. doi: 10. 1016/S0002-9440(10)64036-9.
49. Exner M, Minar E, Mlekusch W, Sabeti S, Amighi J, Lalouschek W, Maurer G, Bieglmayer C, Kieweg H, Wagner O, Schillinger M (2006) Myeloperoxidase predicts progression of carotid stenosis in states of low high-density lipoprotein cholesterol. J Am Coll Cardiol 47(11): 2212-2218. doi: 10. 1016/j. jacc. 2006. 01. 067.
50. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL (2001) Association between myeloperoxidase levels and risk of coronary artery disease. JAMA: J Am Med Assoc 286(17): 2136-2142.
51. Kubala L, Lu G, Baldus S, Berglund L, Eiserich JP (2008) Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease. Clin Chim Acta: Int J Clin Chem 394(1-2): 59-62. doi: 10. 1016/j. cca. 2008. 04. 001.
52. Tretjakovs P, Jurka A, Bormane I, Mikelsone I, Elksne K, Krievina G, Reihmane D, Verbovenko J, Bahs G (2012) Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina. Clinica Chim Acta: Int J of Clin Chem 413(1-2): 25-29. doi: 10. 1016/j. cca. 2011. 10. 009.
53. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM (2007) Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 50(2): 159-165. doi: 10. 1016/j. jacc. 2007. 03. 033.
54. Brevetti G, Schiano V, Laurenzano E, Giugliano G, Petretta M, Scopacasa F, Chiariello M (2008) Myeloperoxidase, but not C-reactive protein, predicts cardiovascular risk in peripheral arterial disease. Eur Heart J 29(2): 224-230. doi: 10. 1093/eurheartj/ehm587.
55. Brennan ML, Penn MS, van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349(17): 1595-1604. doi: 10. 1056/NEJMoa035003.
56. Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SL (2008) Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 29(9): 1096-1102. doi: 10. 1093/eurheartj/ehn071.
57. Iuliano L, Mauriello A, Sbarigia E, Spagnoli LG, Violi F (2000) Radiolabeled native low-density lipoprotein injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque: effect of vitamin E supplementation. Circulation 101(11): 1249-1254.
58. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL (1990) Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10(3): 325-335.
59. Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, Kornman KS, Berger PB (2007) Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 48(2): 425-433. doi: 10. 1194/jlr. M600361-JLR200.
60. Holvoet P, Vanhaecke J, Janssens S, van de Werf F, Collen D (1998) Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98(15): 1487-1494.
61. Sigala F, Kotsinas A, Savari P, Filis K, Markantonis S, Iliodromitis EK, Gorgoulis VG, Andreadou I (2010) Oxidized LDL in human carotid plaques is related to symptomatic carotid disease and lesion instability. J Vasc Surg 52(3): 704-713. doi: 10. 1016/j. jvs. 2010. 03. 047.
62. Naruko T, Ueda M, Ehara S, Itoh A, Haze K, Shirai N, Ikura Y, Ohsawa M, Itabe H, Kobayashi Y, Yamagishi H, Yoshiyama M, Yoshikawa J, Becker AE (2006) Persistent high levels of plasma oxidized low-density lipoprotein after acute myocardial infarction predict stent restenosis. Arterioscler Thromb Vasc Biol 26(4): 877-883. doi: 10. 1161/01. ATV. 0000209886. 31510. 7f.
63. Shimada K, Mokuno H, Matsunaga E, Miyazaki T, Sumiyoshi K, Miyauchi K, Daida H (2004) Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis 174(2): 343-347. doi: 10. 1016/j. atherosclerosis. 2004. 01. 029.
64. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, Harris TB (2004) The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 53(4): 1068-1073.
65. Wu T, Willett WC, Rifai N, Shai I, Manson JE, Rimm EB (2006) Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U. S. men and women? J Am Coll Cardiol 48(5): 973-979. doi: 10. 1016/j. jacc. 2006. 03. 057.
66. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB (2005) Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353(1): 46-57. doi: 10. 1056/NEJMoa043175.
67. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, Xu Q, Bergmark C, Weger S, Oberhollenzer F, Witztum JL (2006) Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 47(11): 2219-2228. doi: 10. 1016/j. jacc. 2006. 03. 001.
68. Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Tsimikas S (2011) Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res 52(10): 1829-1836. doi: 10. 1194/jlr. M015776.
69. Koenig W, Karakas M, Zierer A, Herder C, Baumert J, Meisinger C, Thorand B (2011) Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg Study. Clin Chem 57(8): 1196-1200. doi: 10. 1373/clinchem. 2011. 165134.
70. Thornalley PJ (1998) Cell activation by glycated proteins: AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 44(7): 1013-1023.
71. Ceriello A (1999) Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr Metab 12(1): 42-46.
72. Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H (2001) Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 85(1): 87-91.
73. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, Lyons TJ (1993) Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Investig 91(6): 2470-2478. doi: 10. 1172/JCI116482.
74. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108(9): 1070-1077. doi: 10. 1161/01. CIR. 0000086014. 80477. 0D.
75. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y, Ohtoshi K, Hayaishi-Okano R, Kosugi K, Hori M, Yamasaki Y (2005) Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28(11): 2716-2721.
76. Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Baccarin L, Laverda B, Fedele D (2007) Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 30(3): 670-676. doi: 10. 2337/dc06-1508.
77. Onorato JM, Thorpe SR, Baynes JW (1998) Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann N Y Acad Sci 854: 277-290.
78. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipollone F (2006) Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 26(12): 2716-2723. doi: 10. 1161/01. ATV. 0000249630. 02085. 12.
79. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM (2008) Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA: J Am Med Assoc 300(18): 2123-2133. doi: 10. 1001/jama. 2008. 600.
80. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ (2003) Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 361(9374): 2017-2023. doi: 10. 1016/S0140-6736(03)13637-9.